FDA
-
-
-
-
-
-
-
Taysha Gene Therapies (TSHA) PT Raised to $17 at Canaccord
-
-
-
-
-
-
-
Goldman Sachs Upgrades Taysha Gene Therapies (TSHA) to Buy
-
-
-
-
-
-
-
Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting
-
-
-
-
-
-
-
Taysha Gene Therapies (TSHA) announces presentations for TSHA-102 program
-
-
-
-
-
-
-
Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Taysha Gene Therapies (TSHA) Announces Positive Clinical Data Across Adult and Pediatric Patients from Low Dose Cohort in REVEAL Phase 1/2 Trials
-
-
-
-
-
-
-
Taysha Gene Therapies Announces Updates to TSHA-102 Clinical Program in Rett Syndrome
-
324,023 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

